News & Updates
Filter by Specialty:
Low visceral fat area predicts poor survival in cancer patients
Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.
Low visceral fat area predicts poor survival in cancer patients
02 Oct 2023Living near a major road may accelerate lung function decline in IPF patients
People with idiopathic pulmonary fibrosis (IPF) who live near a major road tend to have a faster decrease in lung function, according to a study in Australia. Likewise, increased exposure to fine particulate matter (<2.5 μm, PM2.5) is associated with a higher rate of annual decline in diffusing capacity of the lungs for carbon monoxide (DLco).
Living near a major road may accelerate lung function decline in IPF patients
02 Oct 2023Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).
Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
02 Oct 2023Pretreatment serum CEA level predicts survival in NSCLC
Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.
Pretreatment serum CEA level predicts survival in NSCLC
29 Sep 2023Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.